Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy
暂无分享,去创建一个
[1] B. Maron. Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.
[2] J. Schmitt,et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. , 2002, The Journal of clinical investigation.
[3] N. Smedira,et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.
[4] B. Maron,et al. Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.
[5] S. Ommen,et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. , 2001, Journal of the American College of Cardiology.
[6] M. Entman,et al. Angiotensin II Blockade Reverses Myocardial Fibrosis in a Transgenic Mouse Model of Human Hypertrophic Cardiomyopathy , 2001, Circulation.
[7] P. Elliott,et al. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.
[8] B. Maron,et al. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[9] D. Corrado,et al. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. , 2000, Journal of the American College of Cardiology.
[10] B. Kuśmierczyk-Droszcz,et al. Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy. , 2000, European heart journal.
[11] M. Link,et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.
[12] A Natale,et al. False positive head-up tilt: hemodynamic and neurohumoral profile. , 2000, Journal of the American College of Cardiology.
[13] M. Josephson,et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.
[14] F O Mueller,et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. , 1996, JAMA.
[15] W. Williams,et al. Hypertrophic cardiomyopathy. Clinical spectrum and treatment. , 1995, Circulation.
[16] U. Sigwart. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy , 1995, The Lancet.
[17] M. Burch,et al. Hypertrophic cardiomyopathy. , 1994, Archives of disease in childhood.
[18] M. Z. Berisso,et al. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population. , 1989, The New England journal of medicine.
[19] E. Braunwald,et al. Idiopathic Hypertrophic Subaortic Stenosis: Clinical Analysis of 126 Patients with Emphasis on the Natural History , 1968, Circulation.
[20] E. Braunwald,et al. Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.
[21] E. Braunwald,et al. Idiopathic Hypertrophic Subaortic Stenosis: II. Operative Treatment and the Results of Pre‐ and Postoperative Hemodynamic Evaluations , 1964, Circulation.
[22] C. Lambrew,et al. Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients , 1964, Circulation.
[23] E. Braunwald,et al. Functional Aortic Stenosis: A Malformation Characterized by Resistance to Left Ventricular Outflow without Anatomic Obstruction , 1959, Circulation.
[24] D TEARE,et al. ASYMMETRICAL HYPERTROPHY OF THE HEART IN YOUNG ADULTS , 1958, British heart journal.